Amino acid compositions and their use in immunosuppression

 

Describe the use of glycine in the manufacture of enteric medicament or nutritional composition for the prevention and/or therapy of renal dysfunction induced by cyclosporine or ascomycin. Specified drug or nutritional composition contain sources of protein, such as sources of protein from soy or milk and/or protein hydrolysates. A method of treating renal dysfunction includes enteral administration to a human or other mammal prior to, simultaneously with or after treatment with cyclosporine or ascomycin medicines or nutritional compositions containing glycine in the amount effective for inhibiting and/or reducing the intensity of symptoms of renal dysfunction. 4 C. and 14 C.p. f-crystals, 5 Il., table 2.

Description text in facsimile form (see graphic part).

Claims

1. The use of glycine in the manufacture of enteric medicament or nutritional composition for the prevention and/or therapy of renal dysfunction induced by cyclosporine or ascomycin, provided that the drug or nutritional composition contains izati.

2. Application under item 1, in which the specified renal dysfunction induced by cyclosporine nephrotoxicity or ascomycin.

3. Application under item 1 or 2, where the drug or nutritional composition further includes a component (I) containing L-arginine or other physiologically acceptable compound associated with the synthesis of nitric oxide, or their mixture.

4. Use PP.1-3, where the nutritional composition is a food Supplement.

5. Application under item 4, where the food additive consists essentially of glycine and a carbohydrate source.

6. Application under item 5, where food additive further includes a source of protein.

7. Use PP.1-3, where the nutritional composition is a complete composition of the diet.

8. Use PP.1-3, where the medicinal product further includes cyclosporine or ascomycin.

9. Application under item 8, wherein the cyclosporine or ascomycin entered for a person or other mammal prior to administration of glycine, before, concurrently or after administration of glycine.

10. Drug or nutritional composition for enteral introduction of a therapeutically effective amount of glycine for the prevention and/or therapy of renal disfunctionality sources of protein, like sources of protein from soy or milk and/or protein hydrolysates.

11. Medicinal product for enteral administration, comprising a therapeutically effective amount of cyclosporine or ascomycin in combination with glycine in an amount effective for inhibiting and/or reducing the intensity of symptoms of renal dysfunction induced by the specified cyclosporine or ascomycin.

12. Drug or nutritional composition for enteral introduction by p. 10 or 11, which additionally contain L-arginine or L-ornithine, where glycine, L-arginine and L-ornithine are the only free amino acids in the specified drug or nutritional composition.

13. Medicinal product for enteral introduction according to any one of paragraphs.10-12, in which the drug-containing cyclosporine or ascomycin, is administered prior to administration of glycine, simultaneously with or after administration of glycine.

14. A method of prophylactic and/or therapeutic treatment of renal dysfunction induced by cyclosporine or ascomycin, including enteral administration to a human or other mammal prior to, simultaneously with or after treatment with cyclosporine or speaker is for inhibiting and/or reducing the intensity of symptoms of renal dysfunction, provided that the drug or nutritional composition contains sources of protein, such as sources of protein from soy or milk and/or protein hydrolysates.

15. The method according to p. 14, where the specified renal dysfunction induced nephrotoxicity of cyclosporine or ascomycin.

16. The method according to p. 14 or 15, where the specified drug or nutritional composition further comprises L-arginine or L-ornithine, or their mixture.

17. The method according to p. 14, comprising the enteral administration to a human or other mammal prior to, simultaneously with or after treatment with cyclosporine or ascomycin medicines or nutritional compositions containing the amino acid component comprising mainly glycine and its physiologically acceptable salts, in an amount effective for inhibiting or reducing symptoms intensity of renal dysfunction.

18. The method according to p. 14, comprising the enteral administration to a human or other mammal prior to, simultaneously with or after treatment with cyclosporine or ascomycin medicines or nutritional compositions containing the amino acid component comprising predominantly glycine, its physiologically acceptable tensively renal dysfunction.

 

Same patents:

The invention relates to medicine, in particular to urology and Nephrology, and for the treatment of acute purulent pyelonephritis

The invention relates to medicine, in particular to oncourology

Pharmaceutical drug // 2213577
The invention relates to medicine

The invention relates to medicine and can be used to treat allergic reactions at a late stage and inflammatory diseases
The invention relates to medicine, in particular, urology

The invention relates to new compounds of the formula I or II or compounds selected from the following group, with activity against receptor calcium, pharmaceutical compositions and methods of treating diseases caused by abnormal mineral homeostasis, hyperparathyroidism, hypercalcemia, malignant tumors, osteoporosis, hypertension and renal osteodystrophies

The invention relates to medicine, namely to Nephrology, and can be used for the treatment of alcohol kidney damage

The invention relates to medicine, in particular to therapy, and relates to methods of treatment of patients with chronic glomerulonephritis

The invention relates to medicine and can be used for treatment of chronic pyelonephritis in the acute stage

The invention relates to medicine, in particular to immunology and Nephrology

The invention relates to the field of medicine and for the solution of cyclosporine

The invention relates to the field of pharmacy and touches the fat emulsion for inhalation

The invention relates to the field of pharmacy and relates to pharmaceutical compositions cyclosporine

The invention relates to medicine, namely, neurology

The invention relates to the preparation, for example, in the form of capsules, soft coated, containing as active ingredient cyclosporine

The invention relates to a method for cyclosporine And high purity by purification of the crude product containing cyclosporiasis complex by multi-step chromatography on silica gel at high load columns from 10 to 52%, using as eluent a mixture of toluene with acetone in an amount of from 10 to 30 vol.% or toluene with ethyl acetate in an amount of from 10 to 35 vol.%, cyclosporine And high purity with content cyclosporine L, U and D less than 0.05% and the content of cyclosporine and < 0,02% vol., industrial method of purification of cyclosporin a from a crude product containing complex cyclosporiasis

The invention relates to medicine, in particular to the microemulsion preconcentrate, including soluble active agent and a carrier, comprising: 1) a hydrophilic phase, which includes dimetridazole and/or lower alkylalkoxy ether, 2) a lipophilic phase, and 3) surfactant

The invention relates to medicine, namely to pharmacology and psychiatry
Up!